- Home
- LUCD vs YARW Comparison
LUCD vs YARW Comparison
Compare LUCD & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCD | YARW |
|---|---|---|
| Founded | 2018 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.9M | 154.5M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LUCD | YARW |
|---|---|---|
| Price | $0.40 | $15.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $4.00 | ★ $57.00 |
| AVG Volume (30 Days) | ★ 8.2M | 157.3K |
| Earning Date | 11-12-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.67 | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,346,000.00 | N/A |
| Revenue This Year | $33.93 | N/A |
| Revenue Next Year | $165.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 79.00 | N/A |
| 52 Week Low | $0.30 | $14.08 |
| 52 Week High | $1.63 | $44.28 |
Technical Indicators
Market Signals| Indicator | LUCD | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 37.39 | 33.91 |
| Support Level | $0.30 | N/A |
| Resistance Level | $1.09 | $20.49 |
| Average True Range (ATR) | 0.06 | 1.95 |
| MACD | 0.01 | -0.19 |
| Stochastic Oscillator | 36.58 | 36.02 |
Price Performance
Historical ComparisonAbout LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.